Holen Sie sich die Stockscreener-App
0.69
16.95%
0.10
Handel nachbörslich:
.69
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SCYX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.59
Offen:
$0.6075
24-Stunden-Volumen:
2.69M
Relative Volume:
5.33
Marktkapitalisierung:
$28.93M
Einnahmen:
$3.26M
Nettoeinkommen (Verlust:
$-19.52M
KGV:
-1.725
EPS:
-0.4
Netto-Cashflow:
$-24.10M
1W Leistung:
+16.93%
1M Leistung:
-10.39%
6M Leistung:
-13.69%
1J Leistung:
-41.53%
1-Tages-Spanne:
$0.6075
$0.7271
1-Wochen-Bereich:
$0.565
$0.7271
52-Wochen-Spanne:
$0.565
$1.49
Scynexis Inc Stock (SCYX) Company Profile
Firmenname
Scynexis Inc
Sektor
Telefon
201-884-5485
Adresse
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Vergleichen Sie SCYX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
0.69 | 24.76M | 3.26M | -19.52M | -24.10M | -0.40 |
|
ZTS
Zoetis Inc
|
115.89 | 51.60B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.51B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.60 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.28 | 28.04B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.72 | 20.52B | 3.08B | 1.24B | 1.07B | 25.61 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-01-22 | Eingeleitet | Guggenheim | Buy |
| 2021-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-11 | Hochstufung | Needham | Hold → Buy |
| 2018-06-27 | Eingeleitet | Maxim Group | Buy |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2017-07-10 | Eingeleitet | ROTH Capital | Buy |
| 2017-05-09 | Herabstufung | Needham | Buy → Hold |
| 2017-03-03 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-10-07 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2016-08-17 | Eingeleitet | Guggenheim | Buy |
| 2016-08-09 | Bestätigt | Needham | Buy |
| 2016-08-09 | Hochstufung | WBB Securities | Speculative Buy → Buy |
| 2016-03-28 | Eingeleitet | Brean Capital | Buy |
| 2015-12-29 | Eingeleitet | WBB Securities | Speculative Buy |
| 2015-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-06-10 | Eingeleitet | Needham | Buy |
| 2014-05-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2014-05-29 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Scynexis Inc Aktie (SCYX) Neueste Nachrichten
Will SCYNEXIS Inc. (135A) stock outperform foreign stocksJuly 2025 Action & Risk Managed Trade Strategies - newser.com
Analyzing recovery setups for SCYNEXIS Inc. investorsFed Meeting & Fast Gain Stock Trading Tips - newser.com
Will SCYNEXIS Inc. stock recover faster than peersJuly 2025 Update & Technical Pattern Alert System - newser.com
Scynexis Transfers Brexafemme New Drug Application to GSK - MarketScreener
SCYNEXIS, Inc. Completes Transfer of Brexafungerp New Drug Application to Gsk - MarketScreener
Scynexis completes transfer of Brexafemme new drug application to GSK - MarketScreener
SCYNEXIS Completes BREXAFEMME NDA Transfer to GSK, Positioning for Future Milestones and Royalties - Quiver Quantitative
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK - The Manila Times
Scynexis completes transfer of Brexafemme New Drug Application To GSK - TradingView
SCYNEXIS (NASDAQ: SCYX) transfers BREXAFEMME NDA to GSK, up to $145.5M - Stock Titan
Why SCYNEXIS Inc. (135A) stock stays resilientEarnings Recap Report & Low Risk High Win Rate Stock Picks - newser.com
Is SCYNEXIS Inc. stock attractive for passive investorsMarket Sentiment Report & Long-Term Safe Investment Plans - newser.com
How to build a dashboard for SCYNEXIS Inc. stockEarnings Overview Report & Risk Controlled Daily Trade Plans - newser.com
Scynexis fungerps among funding recipients - BioWorld MedTech
SCYNEXIS receives $7 million annual grant for antifungal research By Investing.com - Investing.com Nigeria
SCYX Secures Federal Grant for Antifungal Research - GuruFocus
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections - The Manila Times
SCYNEXIS Receives $35 Million NIH Grant to Develop Next-Generation Antifungal Therapies - Quiver Quantitative
Scynexis (NASDAQ: SCYX) fungerps program included in $7M NIH CETR grant - Stock Titan
Is SCYNEXIS Inc. (135A) stock considered safe havenGap Up & Smart Allocation Stock Tips - newser.com
Why SCYNEXIS Inc. (135A) stock benefits from AI revolutionForecast Cut & AI Forecast Swing Trade Picks - newser.com
Live market analysis of SCYNEXIS Inc.July 2025 Recap & Community Verified Trade Signals - newser.com
Will SCYNEXIS Inc. (135A) stock deliver stable dividendsJuly 2025 Closing Moves & Weekly Top Gainers Alerts - newser.com
How geopolitical tensions affect SCYNEXIS Inc. stockEarnings Recap Summary & Consistent Return Investment Signals - newser.com
SCYX | SCYNEXIS Inc. SEC Filings - MarketWatch
How SCYNEXIS Inc. (135A) stock compares with tech leadersPortfolio Gains Report & Weekly High Return Stock Forecasts - Fundação Cultural do Pará
Is SCYNEXIS Inc. stock attractive for ETFsPortfolio Performance Report & Free Technical Confirmation Trade Alerts - Fundação Cultural do Pará
Is SCYNEXIS Inc. stock ready for a breakoutEarnings Summary Report & Capital Efficient Trading Techniques - newser.com
Can SCYNEXIS Inc. stock maintain growth trajectoryLong Setup & Risk Adjusted Swing Trade Ideas - newser.com
Is SCYNEXIS Inc. stock bottoming outForecast Cut & AI Driven Stock Movement Reports - newser.com
Here's Why We're A Bit Worried About SCYNEXIS' (NASDAQ:SCYX) Cash Burn Situation - Yahoo Finance
Finanzdaten der Scynexis Inc-Aktie (SCYX)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.17%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):